New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 4, 2014
17:06 EDTDRTXDurata Therapeutics says data from DISCOVER subject of NEJM article
Durata Therapeutics announced the Phase 3 data from its DISCOVER program evaluating dalbavancin for the treatment of acute bacterial skin and skin structure infections, ABSSSI, in adults was the subject of an article published in the latest edition of the New England Journal of Medicine, NEJM, "Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection." The article highlights the benefits of dalbavancin and its potential to change the treatment paradigm for ABSSSI patients.The DISCOVER studies are identical multicenter, double-blind, randomized clinical trials that included more than 1,300 adults with ABSSSI from the United States, Europe, Asia and South Africa. In the DISCOVER studies, adult patients were treated for 2 weeks either with intravenous dalbavancin once weekly or with intravenous vancomycin . Dalbavancin achieved its primary endpoint in both the DISCOVER 1 and DISCOVER 2 studies of non-inferiority to vancomycin by demonstrating cessation of spread of the erythema associated with the lesion, as well as the resolution of fever 48-72 hours following initiation of treatment. The secondary endpoint of clinical success at end of treatment, EOT, the expected primary endpoint for regulatory review in Europe, was also met.
News For DRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 15, 2014
10:02 EDTDRTXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:54 EDTDRTXDurata Therapeutics downgraded to Neutral from Buy at Roth Capital
Subscribe for More Information
October 14, 2014
10:01 EDTDRTXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:10 EDTDRTXDurata Therapeutics downgraded to Neutral from Outperform at Credit Suisse
Durata Therapeutics (DRTX ) is being acquired by Actavis (ACT) for $23 per share and $5 in contingent value rights and Credit Suisse does not believe a higher bid will emerge.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use